Clinipath to Operate Medical Lab for CVSKL Cardiac and Vascular Specialist Centre

Share Article

Cardiac Vascular Sentral Kuala Lumpur (CVSKL), one of the region’s first private cardiac and vascular specialist hospitals, has selected Clinipath Malaysia Sdn Bhd (Clinipath) to operate the advanced medical laboratory in Kuala Lumpur Sentral. CVSKL started operations on 28 November 2017, full operations commenced the following day, including inpatient, outpatient and emergency services.

Cardiac Vascular Sentral Kuala Lumpur (CVSKL), one of the region’s first private cardiac and vascular specialist hospitals, has selected Clinipath Malaysia Sdn Bhd (Clinipath) to operate the advanced medical laboratory in Kuala Lumpur Sentral.

Clinipath, a wholly-owned subsidiary of Malaysian Genomics Resource Centre Berhad (Malaysian Genomics), is one of Malaysia’s largest private pathology service providers, with a network of laboratories across Peninsula and East Malaysia. The comprehensive range of clinical pathology testing services offered by Clinipath will help CVSKL’s doctors and specialists to provide precision and personalised care for their patients as doctors and surgeons increasingly require fast, accurate and reliable clinical information to properly diagnose and treat their patients’ various cardiovascular conditions.

According to the Health Ministry, cardiovascular diseases (CVDs) have been the leading cause of death in Malaysia for more than a decade, and this group of diseases are responsible for one-quarter of hospital deaths. Alarmingly, more young people are now being affected by CVDs. According to the National Cardiovascular Database Annual Report, almost a quarter of heart patients in Malaysia are now below the age of 50. This phenomenon is likely caused by the current prevalence of a sedentary lifestyle and unhealthy dietary habits in Malaysia.    

“With Malaysia having one of the highest mortality rates for cardiovascular diseases in the world, it is vital for CVSKL to be modern and well-equipped in delivering excellent care to its patients. The broad range of tests offered by Clinipath can help CVSKL to evaluate and improve its patients’ cardiovascular diagnoses, and provide more effective treatment to those suffering from cardiovascular diseases,” said Tan Sri Dato’ Dr Yahya Awang, Chairman of CVSKL.

“With the rising need to have more accurate assessments for diagnosis and treatment, Clinipath’s role is to provide CVSKL with better access to timely and meaningful clinical information in order to improve patients’ treatment outcomes, and more importantly, save lives. Timely management and treatment of diseases can make a difference between life and death,” said Sasha Nordin, Chief Operating Officer, Malaysian Genomics.

CVSKL started operations on 28 November 2017, full operations commenced the following day, including inpatient, outpatient and emergency services.

About Malaysian Genomics Resource Centre Berhad (Malaysian Genomics)
Malaysian Genomics is a pioneer in genome sequencing, bioinformatics analysis and genetic screening services. Since 2004, Malaysian Genomics has developed extensive pipelines in the sequencing and analysis of human, animal, plant and microbial genomes for clients locally and globally. In 2010, its share was listed on Bursa Malaysia. In 2017, it fully acquired one of the country’s largest private pathology service companies, Clinipath (M) Sdn Bhd. Today, Malaysian Genomics is focused on merging the latest in genetic testing with pathology to enable precision and personalised healthcare among doctors.

About Clinipath Malaysia Sdn Bhd (Clinipath)
Clinipath is one of Malaysia’s largest independent home-grown pathology service providers, having built a nationwide network of 17 branches over the past 20 years. Clinipath offers a complete range of pathology testing services, with more than 1,300 tests under immunology, microbiology, histopathology, haematology, cytology and biochemistry. It also offers the latest in genetic screening and diagnostic tests. The company employs 200 employees, including the country’s finest pathologists. It has been ISO 15189 accredited since 2010. Clinipath is a wholly-owned subsidiary of Malaysian Genomics Resource Centre Berhad, a pioneer in genome sequencing and analysis, and genetic screening services in Malaysia.

About Cardiac Vascular Sentral Kuala Lumpur (CVSKL)
Cardiac Vascular Sentral Kuala Lumpur (CVSKL) is an integrated Cardiovascular Medical Centre specialising in comprehensive modern care for patients with cardiac and vascular diseases. Backed by a sterling track record of achievements and top-notch expertise, our hand-picked team of dedicated cardiologists, cardiothoracic surgeons, vascular surgeons and cardiac anaesthesiologists ensure premier standards of evidence-based and professional care. Here, patients will enjoy the finest care and consultation quality from equally eminent physicians, radiologists, cardiac and vascular technicians, alongside excellent nursing and other support staff.

Comprising a 60 bedded Cardiac and Vascular Medical Centre equipped with state-of-the-art facilities, the CVSKL building houses an all-encompassing range of cardiology, cardiothoracic, and vascular diagnostic, therapeutic and preventive services. Also, a highly strategic location in the transportation hub of Kuala Lumpur Sentral offers unparalleled accessibility by LRT, MRT, train, bus, taxi or KLIA Express within the city’s thriving heart. For added convenience, visitors can find within walking distance a wealth of hotels, service apartments and a shopping mall.

For media enquiries, please contact Joseph Neo at +603 2283 1820

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joseph Neo
joseph@mgrc.com.my
+60 322831820 Ext: 106
Email >
Visit website